Acumen Pharmaceuticals (NASDAQ:ABOS) Earns “Buy” Rating from BTIG Research

Acumen Pharmaceuticals (NASDAQ:ABOS)‘s stock had its “buy” rating reiterated by investment analysts at BTIG Research in a research note issued to investors on Thursday,Benzinga reports. They currently have a $8.00 target price on the stock. BTIG Research’s price target suggests a potential upside of 253.98% from the company’s current price.

ABOS has been the topic of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research note on Friday, January 9th. Wall Street Zen downgraded Acumen Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

Acumen Pharmaceuticals Stock Down 11.4%

Shares of NASDAQ ABOS opened at $2.26 on Thursday. The company has a quick ratio of 6.02, a current ratio of 6.02 and a debt-to-equity ratio of 0.29. The business’s 50 day moving average is $2.70 and its two-hundred day moving average is $2.16. Acumen Pharmaceuticals has a 52-week low of $0.86 and a 52-week high of $3.60. The firm has a market cap of $136.89 million, a price-to-earnings ratio of -1.12 and a beta of 0.21.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.09. The firm had revenue of ($0.09) million for the quarter. Research analysts predict that Acumen Pharmaceuticals will post -1.56 EPS for the current year.

Insider Buying and Selling at Acumen Pharmaceuticals

In other news, CEO Daniel Joseph Oconnell sold 37,755 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $1.99, for a total transaction of $75,132.45. Following the sale, the chief executive officer owned 619,982 shares of the company’s stock, valued at approximately $1,233,764.18. This trade represents a 5.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 149,818 shares of company stock worth $285,057. 9.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Acumen Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ABOS. Dimensional Fund Advisors LP raised its holdings in Acumen Pharmaceuticals by 12.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 49,062 shares of the company’s stock worth $104,000 after purchasing an additional 5,538 shares in the last quarter. PFG Investments LLC boosted its holdings in shares of Acumen Pharmaceuticals by 65.2% in the 4th quarter. PFG Investments LLC now owns 19,000 shares of the company’s stock valued at $40,000 after buying an additional 7,500 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Acumen Pharmaceuticals by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 410,206 shares of the company’s stock valued at $866,000 after buying an additional 11,428 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Acumen Pharmaceuticals in the 3rd quarter valued at $27,000. Finally, Independent Advisor Alliance purchased a new position in shares of Acumen Pharmaceuticals in the 4th quarter valued at $40,000. 71.01% of the stock is currently owned by hedge funds and other institutional investors.

Acumen Pharmaceuticals News Summary

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Acumen said it has $36M of funding to advance its EBD program and is targeting an ALTITUDE‑AD Phase II readout in late 2026 — this provides program funding visibility and a clear clinical milestone that could re‑rate shares if results are favorable. Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set an $8 price target, suggesting sizable upside from current levels and giving institutional validation to the company’s clinical strategy. BTIG buy rating and $8 price target coverage
• Positive Sentiment: Q4 results beat on the EPS line (reported $(0.41) vs. $(0.50) consensus), showing a smaller-than-expected loss and suggesting modest operating leverage as programs advance. Acumen Q4 EPS beat and earnings materials
• Neutral Sentiment: Company press release and earnings‑call highlights outlined strategic advances and program updates (full-year financials and business highlights), which provide context but no immediate new financing or partnership decisions. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full-year 2025 financial report reiterates cash burn, program priorities and R&D focus — useful for modeling runway but not a catalyst by itself. Acumen reports financial results and business highlights
• Negative Sentiment: Acumen filed to sell 10.83 million shares of common stock on behalf of holders — a potential secondary that increases near‑term supply and dilution risk, which likely pressured the stock despite operational positives. Acumen files to sell 10.83M shares for holders

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.